TESAMORELIN 20 MG
SKU: CP_TESAMORELIN_20MG_5ML_VIAL
Catalog price · 1 item: US$140.00 (USD)
Product information
Background and evidence boundaries
Tesamorelin is presented as a modified GHRH analogue acting at the pituitary GHRH receptor, with greater resistance to DPP-IV breakdown than native GHRH. The page separates this laboratory material from Egrifta, an approved medicine, and says the medicine's benefits and protocols do not transfer to this vial.
It reviews rat and dog pharmacology, including reversible tissue and blood-chemistry findings during excessive GH/IGF-1 exposure, and animal metabolic and cardiac studies. Clinical discussions concern defined medicines and populations, with glucose-related cautions, hypersensitivity, fluid-retention effects and uncertain long-term safety.
For research handling, it calls for lot-matched documentation and sealed, cold storage away from moisture and light. The product remains research-only, not a treatment for people or animals.
Specifications
| SKU | CP_TESAMORELIN_20MG_5ML_VIAL |
|---|---|
| CATEGORY | Lyophilized Peptide |
| CAS | 901758-09-6 |
| VIAL SIZE | 5 mL |
| FORM | LYOPHILIZED POWDER |
| MOLECULAR WEIGHT | 5135.9 g/mol |
| SEQUENCE | C6H9O-Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly |
| MOLECULAR FORMULA | C221H366N72O67S |
| ITEM ID | 64665 |
| PURITY | 99%+ |
| CAS | 901758-09-6 |
| FORM | LYOPHILIZED POWDER |
| DOSAGE | 20 MG |